Education
About Us
Working with TipRanks
Follow Us
GENinCode UK Ltd. (GB:GENI)
LSE:GENI
GENI Stock Chart & Stats
2.20p
0.20p(5.56%)
At close: 4:00 PM EST
2.20p
0.20p(5.56%)
Day’s Range― - ―
52-Week Range0.90p - 5.50p
Previous CloseN/A
Volume6.76K
Average Volume (3M)1.99M
Market Cap
£7.91M
Enterprise Value765.26K
Total Cash (Recent Filing)£2.50M
Total Debt (Recent Filing)£191.00K
Price to Earnings (P/E)―
Beta-0.31
Next Earnings
Jun 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding753,041,140
10 Day Avg. Volume166,671
30 Day Avg. Volume1,986,185
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.90
Price to Sales (P/S)2.46
P/FCF Ratio-1.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrendThe company has delivered a steady increase in revenue (2020–2024) and shows improving gross margin and free cash flow trends. Sustained top-line growth plus margin improvement supports a multi-month path to narrowing losses and eventual operating leverage if commercial traction continues.
Low Debt BurdenMaintaining low debt reduces interest expense and bankruptcy risk for a growth-stage diagnostics firm that is still loss-making. This conservatism preserves financial optionality, enabling the company to raise capital or invest in commercialization without heavy leverage constraints over the coming months.
Focused Precision-Diagnostics BusinessA clear focus on validated genetic/genomic tests and interpretation services for clinical decision-making (esp. cardiovascular risk) aligns with structural trends in precision medicine. Clinical validation and partner-oriented services create durable competitive positioning and higher switching costs.
Bears Say
Persistent Net LossesRecurring net losses and negative operating margins mean the business has not yet reached sustainable profitability. Persistent losses erode shareholder equity, increase dependence on external funding, and raise execution risk until the company secures consistent positive operating income.
Negative Operating Cash FlowMaterially negative operating cash flow indicates the core business does not generate sufficient cash, forcing reliance on financing activities. This constrains reinvestment in commercialization and R&D and creates structural funding risk if capital markets tighten.
Declining / Historical Negative EquityA shrinking equity base and past negative equity reduce balance-sheet resilience and borrowing capacity. This structural weakness limits strategic flexibility, increases vulnerability to shocks, and can hinder long-term partnerships or regulatory initiatives that require financial stability.
GENinCode UK Ltd. News
GENI FAQ
What was GENinCode UK Ltd.’s price range in the past 12 months?
GENinCode UK Ltd. lowest share price was 0.90p and its highest was 5.50p in the past 12 months.
What is GENinCode UK Ltd.’s market cap?
GENinCode UK Ltd.’s market cap is £7.91M.
When is GENinCode UK Ltd.’s upcoming earnings report date?
GENinCode UK Ltd.’s upcoming earnings report date is Jun 09, 2026 which is in 106 days.
How were GENinCode UK Ltd.’s earnings last quarter?
GENinCode UK Ltd. released its earnings results on Sep 30, 2025. The company reported -0.012p earnings per share for the quarter, the consensus estimate of -0.012p by 0p.
Is GENinCode UK Ltd. overvalued?
According to Wall Street analysts GENinCode UK Ltd.’s price is currently Overvalued.
Does GENinCode UK Ltd. pay dividends?
GENinCode UK Ltd. does not currently pay dividends.
What is GENinCode UK Ltd.’s EPS estimate?
GENinCode UK Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GENinCode UK Ltd. have?
GENinCode UK Ltd. has 753,041,140 shares outstanding.
What happened to GENinCode UK Ltd.’s price movement after its last earnings report?
GENinCode UK Ltd. reported an EPS of -0.012p in its last earnings report, expectations of -0.012p. Following the earnings report the stock price went down -14.286%.
Which hedge fund is a major shareholder of GENinCode UK Ltd.?
Currently, no hedge funds are holding shares in GB:GENI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GENinCode UK Ltd.
GENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test, which analyzes the seven genes associated with familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test that analyzes 12 genetic variants related to hereditary thrombophilia and the risk of thrombosis; and Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Oxford, the United Kingdom.
Technical Analysis
Options Prices
Currently, No data available
---